Prospective study of preventive Foscarnet sodium administration to confirm the safety and preventive effect of HHV-6 encephalitis after hematopoietic stem cell transplantation

Prospective study of preventive Foscarnet sodium administration to confirm the safety and preventive effect of HHV-6 encephalitis after hematopoietic stem cell transplantation - Preventive therapy using Foscarnet for the HHV-6 infection after hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001706

Enrollment

Registered

2009-02-13

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic disorder, who receive hematopoietic stem cell transplantation (HSCT) from alternative donor

Interventions

We administer PFA 90mg/kg/day from day +7 to day +21 in bone marrow transplant/peripheral blood stem cell transplant receipient and to day +25 in cord blood transplant receipient. During the PFA admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hematologic disease who are transplanted from alternative donor.

Exclusion criteria

Exclusion criteria: 1. Hypersensitive for PFA 2. Existence of comorbid disease, grade 3 or more in CTCAE v3.0 (except renal insufficiency) 3. Existence of renal insufficiency, grade 2 or more in CTCAE v3.0 4. Unsuitable for enrollment judged by attending physian

Design outcomes

Primary

Measure	Time frame
Safety of PFA administration at early post-HSCT period	—

Countries

Japan

Contacts

Public ContactISHIYAMA, Ken

Graduate School of Medical Science, Kanazawa University Cellular transplantation biology

ishiyamak@med3.m.kanazawa-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026